Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Study Here
Learn More
Share
Our Strategies to Deliver Value
Johnson & Johnson is committed to developing procurement relationships based on trust. We drive growth while maintaining the highest standards through industry-leading supplier innovation, quality and reliability.
-
Growth & InnovationWe aim to own and shape a diverse supplier base that delivers high quality, compliant and reliable products and services.
Our suppliers are encouraged to source innovative solutions, and deliver new business models that contribute to our mutual objectives for growth and streamlined processes. We embrace new technology whenever it may help us meet the needs of our patients and consumers. -
Investing in Our FutureWe track new market developments and seek suppliers who understand emerging trends and plan their business accordingly. We forge long-term relationships with organizations that collaborate with us to successfully bring their innovations to the marketplace.
We follow a procurement approach that is rooted in Our Credo. We strive to obtain the highest-quality products and services at a fair cost, representing the best overall value for our companies. -
Global Diversity, Citizenship and SustainabilityEmbracing our role as an industry leader, Johnson & Johnson shapes and upholds the highest standards for responsible sourcing and corporate citizenship.
We further differentiate Johnson & Johnson by working with suppliers to accelerate environmental and social improvements across the value chain. We anticipate and manage risk, and ensure compliance with all procurement policies and processes. -
Develop Our Diverse, Global Supply BaseWe build and develop a global group of suppliers that reflects the diversity of our patients and customers, and our commitment to inclusion. The Supplier Diversity Program is designed to ensure that businesses of diverse backgrounds and ownership have the opportunity to become valued suppliers.
Since starting our Supplier Diversity Program in 1998, our total spending with small businesses and diverse-owned suppliers has been over one billion dollars annually.
In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.
On the next episode of "The Road to a Vaccine," host Lisa Ling delves into how the pandemic is affecting parents, children and school staff. We sat down with one of the upcoming guests, school nurse Robin Cogan, to find out the most pressing questions on her mind—and those of moms and dads.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
